-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bionomics (NASDAQ:BNOX) Given "In-Line" Rating at Evercore ISI
Bionomics (NASDAQ:BNOX) Given "In-Line" Rating at Evercore ISI
Evercore ISI restated their in-line rating on shares of Bionomics (NASDAQ:BNOX – Get Rating) in a research note released on Tuesday, Benzinga reports. Evercore ISI currently has a $6.00 price target on the stock, down from their previous price target of $17.00.
Several other equities research analysts have also recently issued reports on BNOX. Loop Capital initiated coverage on Bionomics in a report on Tuesday, November 1st. They set a buy rating and a $23.00 price objective on the stock. HC Wainwright cut Bionomics from a buy rating to a neutral rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $16.67.
Get Bionomics alerts:Bionomics Stock Performance
BNOX stock opened at $4.94 on Tuesday. Bionomics has a 52-week low of $4.94 and a 52-week high of $13.76. The stock's fifty day simple moving average is $7.62 and its 200-day simple moving average is $7.37.
Bionomics Company Profile
(Get Rating)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Further Reading
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
Evercore ISI restated their in-line rating on shares of Bionomics (NASDAQ:BNOX – Get Rating) in a research note released on Tuesday, Benzinga reports. Evercore ISI currently has a $6.00 price target on the stock, down from their previous price target of $17.00.
据Benzinga报道,Evercore ISI在周二发布的一份研究报告中重申了对生物科技股票的在线评级(BNOX-GET Rating)。Evercore ISI目前对该股的目标价为6.00美元,低于此前17.00美元的目标价。
Several other equities research analysts have also recently issued reports on BNOX. Loop Capital initiated coverage on Bionomics in a report on Tuesday, November 1st. They set a buy rating and a $23.00 price objective on the stock. HC Wainwright cut Bionomics from a buy rating to a neutral rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $16.67.
其他几位股票研究分析师最近也发布了关于BNOX的报告。Loop Capital在11月1日星期二的一份报告中发起了对生物学的报道。他们为该股设定了买入评级和23.00美元的目标价。在周一的一份报告中,HC Wainwright将Bionomics的评级从买入下调至中性。两名分析师对该股的评级为持有,四名分析师对该股的评级为买入。根据MarketBeat的数据,该股的共识评级为适度买入,共识目标价为16.67美元。
Bionomics Stock Performance
生态类股表现
BNOX stock opened at $4.94 on Tuesday. Bionomics has a 52-week low of $4.94 and a 52-week high of $13.76. The stock's fifty day simple moving average is $7.62 and its 200-day simple moving average is $7.37.
周二,BNOX的股票开盘报4.94美元。Bionomics的52周低点为4.94美元,52周高点为13.76美元。该股的50日简单移动均线为7.62美元,200日简单移动均线为7.37美元。
Bionomics Company Profile
生物制药公司简介
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
生物制药有限公司是一家临床阶段的生物制药公司,发现和开发治疗中枢神经系统疾病和癌症的新药候选药物。该公司的主要候选药物包括BNC210,这是一种A7烟碱型乙酰胆碱受体的负变构调节剂,正处于治疗社交焦虑障碍的第二阶段临床试验和治疗创伤后应激障碍的2b阶段临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- 免费获取StockNews.com关于生物学的研究报告(BNOX)
- 凯洛格的股东有店内奖品吗?
- AMC的麻烦会影响其房东EPR Properties吗?
- 通用磨坊撤退至更具吸引力的地区
- 如果马斯克退出Twitter,特斯拉的股价会上涨吗?
- 2023年值得关注的5个下跌但不是下跌的股票
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bionomics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧